Fusion Antibodies (LON:FAB) Shares Down 20.3% – Here’s Why

Fusion Antibodies plc (LON:FAB)’s share price fell 20.3% during trading on Monday . The stock traded as low as GBX 9 and last traded at GBX 9.05. Approximately 2,113,557 shares traded hands during mid-day trading, an increase of 407% from the average session volume of 416,821 shares. The stock had previously closed at GBX 11.35.

Fusion Antibodies Trading Down 20.3%

The company has a debt-to-equity ratio of 92.42, a current ratio of 1.80 and a quick ratio of 2.36. The firm has a fifty day simple moving average of GBX 10.89 and a two-hundred day simple moving average of GBX 12.20. The firm has a market capitalization of £11.33 million, a P/E ratio of -6.03 and a beta of 1.24.

Fusion Antibodies (LON:FAB) last issued its quarterly earnings results on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative net margin of 91.92% and a negative return on equity of 210.32%. On average, equities research analysts anticipate that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.